Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

An accidental household outbreak of paliperidone palmitate poisoning via pancake consumption in Lianyungang, China - Zhang T, Li Z, Luo P, Sun Q.
INTRODUCTION: At 11:20 on 26 May 2018, a physician from Lianyungang No. 1 People's Hospital, China, reported that six family members were being treated in the hospital with symptoms from an unknown cause. METHODS: A case series for a food poisoning... (Source: SafetyLit)
Source: SafetyLit - May 31, 2021 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

CHMP Backs Generic Paliperidone for Schizophrenia CHMP Backs Generic Paliperidone for Schizophrenia
Paliperidone Janssen-Cilag International, a generic of Xeplion, is for maintenance treatment of schizophrenia in adults stabilized with paliperidone or risperidone and select other cases.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2020 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” sai...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

ANI Announces Launch of Paliperidone Extended-Release Tablets
BAUDETTE, Minn., Jan. 14, 2020 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The current annual U.S... Biopharmaceuticals, Generics, Product Launch ANI Pharmaceuticals, paliperidone, schizophrenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 14, 2020 Category: Pharmaceuticals Source Type: news

Once-every-3-month paliperidone palmitate costs evaluated
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2019 Category: Drugs & Pharmacology Source Type: news

Teva Pharmaceuticals, USA Extends Voluntary Nationwide Recall to Consumer/User Level for One Lot of Paliperidone Extended-Release Tablets, 3mg, 90 Count Bottles Distributed Under the Actavis Pharma Inc. Label Due to Dissolution Test Failure
Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles that was distributed under the Actavis Pharma Inc. label. In coordination with FDA, Teva is extending this recall to the CONSUMER/USER level. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 25, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Delayed-onset toxicity in an adolescent case following attempted suicide with an overdose of paliperidone intake - Yaylac ı F, Küçük Ö, Erkuran HO.
Paliperidone is a relatively novel atypical antipsychotic drug that is currently used to treat schizophrenia in adolescents and adults. The drug was generated by combining the active metabolite of risperidone, 9-hydroxyrisperidone, with osmotic controlled-... (Source: SafetyLit)
Source: SafetyLit - July 18, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Long-Acting Injectables Yield Similar Benefit in Schizophrenia Long-Acting Injectables Yield Similar Benefit in Schizophrenia
Aripiprazole lauroxil once every 2 months provided similar significant improvement in schizophrenia symptoms as once per month paliperidone palmitate.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 11, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with ... Biopharmaceuticals Alkermes, ALPINE study, ARISTADA, INVEGA SUSTENN, schizophrenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 9, 2019 Category: Pharmaceuticals Source Type: news

A case report of guardian-consent forced paliperidone palmitate for behavioral disturbance due to traumatic brain injury - Douglass AR, Smyth U.
Psychosis after traumatic brain injury (TBI) occurs in up to 10% of cases. Although guideline consensus is lacking regarding drugs of choice for this condition, current literature points to the use of atypical antipsychotics. This case describes a 58-year-... (Source: SafetyLit)
Source: SafetyLit - July 5, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

FDA Adds Study Data to Schizophrenia Drug Labeling FDA Adds Study Data to Schizophrenia Drug Labeling
The FDA has approved inclusion of'real-world'data from the phase 3 PRIDE trial in product labeling for the once-monthly antipsychotic paliperidone palmitate in schizophrenia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

LANDMARK SCHIZOPHRENIA DATA THAT BRINGS HOPE IN BREAKING THE CYCLE OF HOSPITALIZATION AND INCARCERATION RECEIVES FDA APPROVAL FOR INCLUSION IN INVEGA SUSTENNA ® (paliperidone palmitate) LABEL
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 3, 2018 Category: Pharmaceuticals Source Type: news

Abilify vs. Invega
Title: Abilify vs. InvegaCategory: MedicationsCreated: 9/29/2017 12:00:00 AMLast Editorial Review: 9/29/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 29, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, in...
Source: JEMS Patient Care - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, in...
Source: JEMS: Journal of Emergency Medical Services News - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, in...
Source: JEMS Patient Care - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

Invega (Paliperidone) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 21, 2017 Category: Drugs & Pharmacology Source Type: news

Paliperidone Manufacturer Issues Urgent Recall Paliperidone Manufacturer Issues Urgent Recall
Drug maker Teva has issued a voluntary recall of a single lot of paliperidone extended-release tablets because the drug failed test results for dissolution, which could reduce its efficacy.News Alerts (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 16, 2017 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

Paliperidone Drug Manufacturer Issues Recall Paliperidone Drug Manufacturer Issues Recall
Drug maker Teva has issued a voluntary recall of a single lot of paliperidone extended-release tablets because the drug failed test results for dissolution, which could reduce its efficacy.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Teva Pharmaceuticals, USA Extends Voluntary Nationwide Recall to Consumer/User Level for One Lot of Paliperidone Extended-Release Tablets, 3mg, 90 Count Bottles Distributed Under the Actavis Pharma Inc. Label Due to Dissolution Test Failure
Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles that was distributed under the Actavis Pharma Inc. label. In coordination with FDA, Teva is extending this recall to the CONSUMER/USER level. (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 15, 2017 Category: Food Science Source Type: news

Effectiveness of paliperidone depot injection in seriously violent men with comorbid schizophrenia and dissocial personality disorder in a UK high-security hospital - Mortlock AM, Larkin F, Ross CC, Gupta N, Sengupta S, Das M.
BACKGROUND: High-security hospital patients are often complex in presentation and are characterized by treatment resistance, medication nonadherence and history of violence. Paliperidone is licensed both as an oral and depot antipsychotic medication in the... (Source: SafetyLit)
Source: SafetyLit - May 29, 2017 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news

Invega Sustenna (Paliperidone Palmitate Extended-Release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 20, 2017 Category: Drugs & Pharmacology Source Type: news

Invega Trinza (Paliperidone Palmitate Extended-release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Janssen-Cilag receives EC approval for Trevicta for maintenance treatment of schizophrenia
Johnson & Johnson subsidiary Janssen-Cilag International has been granted approval by the European Commission (EC) for the use of Trevicta (paliperidone palmitate a three-monthly injection) for the maintenance treatment of schizophrenia in adult pati… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 1, 2016 Category: Pharmaceuticals Source Type: news

Invega Trinza (Paliperidone Palmitate Extended-release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2016 Category: Drugs & Pharmacology Source Type: news

Safety of Vraylar vs. Other Antipsychotics Drugs Compared in New Drug...
Comparative safety research review covers Abilify (Bristol-Meyers), Fanapt (Novartis), INVEGA (J&J), Risperdal (J&J), Risperdal Consta (Janssen)(PRWeb October 26, 2015)Read the full story at http://www.prweb.com/releases/2015/10/prweb13042760.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 26, 2015 Category: Pharmaceuticals Source Type: news

Janssen submits European extension marketing authorisation application for paliperidone palmitate
First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 26, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Psychiatry Patient care antipsychotic Latest News long-acting therapy paliperidone palmitate schizophrenia xeplion Source Type: news

Invega Trinza (paliperidone palmitate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 4, 2015 Category: Drugs & Pharmacology Source Type: news

Invega Trinza (paliperidone palmitate) for the Treatment for Schizophrenia
Invega Trinza (paliperidone palmitate), an atypical antipsychotic, is a three-month injection that is the first, and only, four-times-a-year drug indicated to treat schizophrenia . (Source: Drug Development Technology)
Source: Drug Development Technology - May 27, 2015 Category: Pharmaceuticals Source Type: news

FDA OKs 3-Month Drug for Schizophrenia
FDA OKs 3-Month Paliperidone (Invega Trinza) for Schizophrenia (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 20, 2015 Category: Journals (General) Source Type: news

FDA OKs 3-Month Paliperidone Injection for Schizophrenia FDA OKs 3-Month Paliperidone Injection for Schizophrenia
The quarterly treatment for schizophrenia must be preceded by monthly injections of Invega Sustenna for at least 4 months. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2015 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

J&J's Schizophrenia Drug Wins FDA Priority Review
The U.S. FDA has granted priority review to J&J's Janssen Pharmaceuticals' new drug application for antipsychotic Invega Trinza. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 19, 2015 Category: Pharmaceuticals Source Type: news

Long-term Injectable Antipsychotic Cuts Schizophrenia RelapseLong-term Injectable Antipsychotic Cuts Schizophrenia Relapse
The long-term formulation of paliperidone, which is currently under FDA review, may be the first atypical antipsychotic administered on a four-times-a-year dosing schedule. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 6, 2015 Category: Psychiatry Tags: Psychiatry News Source Type: news

Relapse Prevention of Schizophrenia: Paliperidone Depot vs. HaloperidolRelapse Prevention of Schizophrenia: Paliperidone Depot vs. Haloperidol
Long-acting injectable antipsychotics may be as effective in preventing relapse in schizophrenia as first-generation oral antipsychotics, but severity of side effects need to be taken into consideration. Evidence-Based Mental Health (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2015 Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news

Risperdal Lawsuit News: Mother Alleges Risperdal, Invega Caused Teen...
The Firm is representing numerous clients who have filed Risperdal lawsuits after allegedly developing gynecomastia, or male breast growth, due to the antipsychotic medication.(PRWeb December 04, 2014)Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/invega-lawsuit/prweb12372984.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 5, 2014 Category: Pharmaceuticals Source Type: news

Janssen seeks FDA approval for its antipsychotic drug to treat schizophrenia
Janssen Research & Development has submitted a new drug application (NDA) for its three-month atypical antipsychotic paliperidone palmitate to the US Food and Drug Administration (FDA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 20, 2014 Category: Pharmaceuticals Source Type: news

European Commission approves Invega for treatment of schizophrenia in adolescents
Janssen-Cilag International’s Invega (paliperidone ER) has received the European Commission’s approval to extend its adult indication for treatment of schizophrenia to include adolescents aged 15 years and older. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 5, 2014 Category: Pharmaceuticals Source Type: news

Antipsychotic medications for schizophrenia compared: Similar results
Among adults with schizophrenia or schizoaffective disorder, treatment with the newer, more costly antipsychotic paliperidone palmitate, compared with the older antipsychotic haloperidol decanoate, found no significant difference on a measure of effectiveness, according to a recent study. Long-acting injectable antipsychotic medications are prescribed to reduce nonadherence to drug therapy and relapse in people diagnosed with a schizophrenia-spectrum disorder. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotic medications has not been previously assessed. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 20, 2014 Category: Science Source Type: news

Long-Acting Treatments for Schizophrenia
Schizophrenia has long presented treatment challenges for both patients who have the mental illness and the treatment providers who want to help them. Many medications prescribed for schizophrenia have traditionally not always been well-tolerated in patients, with sometimes significant side effects in some. Schizophrenia is a condition characterized by the person experiencing hallucinations and/or delusions, sometimes of a persecutory nature. It is usually first diagnosed in young adulthood — typically in a person’s 20s — and more often among men than women. Although usually severe in nature, it is also a...
Source: Psych Central - May 17, 2014 Category: Psychiatry Authors: John M. Grohol, Psy.D. Tags: Antipsychotics Atypical Antipsychotics Disorders General Medications Schizophrenia Treatment Invega Sustenna lai long-acting injectables Medication Noncompliance Paliperidone Psychiatry Psychotic relapse Risperidone Schizophr Source Type: news

Janssen submits sNDAs to FDA for Invega Sustenna to treat schizoaffective disorder
Janssen Pharmaceuticals has submitted supplemental new drug applications (sNDAs) to the US Food and Drug Administration (FDA) seeking approval for its once-monthly atypical long-acting antipsychotic Invega Sustenna (paliperidone palmitate) to treat s… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 13, 2014 Category: Pharmaceuticals Source Type: news

Flood Law Group Now Available to Investigate Claims Related to...
Flood Law Group announced today that it is now available to investigate claims related to complications from taking prescription Invega extended release tablets. Invega, also known by its generic name...(PRWeb May 07, 2014)Read the full story at http://www.prweb.com/releases/invega-complications/flood-law-group/prweb11809557.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 8, 2014 Category: Pharmaceuticals Source Type: news

Long-acting Paliperidone Safe, Effective for Dual PsychosisLong-acting Paliperidone Safe, Effective for Dual Psychosis
Switching patients with dual psychosis from other long-acting and oral antipsychotic medications to long-acting injectable paliperidone palmitate is safe and effective, a small study suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2014 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Janssen reports PALMFlexS trial results of schizophrenia drug Xeplion
Janssen Pharmaceutica has reported encouraging results from the PALMFlexS study, which demonstrated the efficacy, safety and tolerability of Xeplion (paliperidone palmitate) in patients with schizophrenia at various stages of the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - December 2, 2013 Category: Pharmaceuticals Source Type: news

New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
PALMFlexS study better reflects Xeplion® use in everyday clinical practice compared to previous clinical trials BEERSE, Belgium--(Healthcare Sales & Marketing Network)--Janssen Pharmaceutica NV has announced results of the PALMFlexS study during Th... BiopharmaceuticalsJanssen Pharmaceutica, Xeplion, paliperidone, Schizophrenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 29, 2013 Category: Pharmaceuticals Source Type: news

J&J Agrees to Pay $2.2B to Resolve Criminal/Civil Allegations
Justice Department officials alleged that J&J used illegal marketing tactics and kickbacks to persuade physicians and pharmacists to prescribe Risperdal and Invega (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 5, 2013 Category: Pharmaceuticals Source Type: news